Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CG Oncology, Inc. is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. Its primary focus is on non-muscle invasive bladder cancer (NMIBC), especially high-risk patients unresponsive to standard BCG therapy. Cretostimogene is designed as a bladder-sparing, intravesical treatment with potential for monotherapy and combination use, targeting durable complete responses and improved safety compared to existing options.
This description was generated via AI from an annual report. Updated about 1 year ago.